Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' BROLY F' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 33 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Allorge, D; Harlow, J; Boulet, O; Hayhurst, GP; Chowdry, J; Roth, E; Crewe, K; Lo-Guidice, JM; Lhermitte, M; Broly, F; Tucker, GT; Ellis, SW
      In-vitro analysis of the contribution of CYP2D6.35 to ultrarapid metabolism

      PHARMACOGENETICS
    2. Chevalier, D; Cauffiez, C; Bernard, C; Lo-Guidice, JM; Allorge, D; Fazio, F; Ferrari, N; Libersa, C; Lhermitte, M; D'Halluin, JC; Broly, F
      Characterization of new mutations in the coding sequence and 5'-untranslated region of the human prostacyclin synthase gene (CYP8A1)

      HUMAN GENETICS
    3. Eap, CB; Broly, F; Mino, A; Hammig, R; Deglon, JJ; Uehlinger, C; Meili, D; Chevalley, AF; Bertschy, G; Zullino, D; Kosel, M; Preisig, M; Baumann, P
      Cytochrome P450 2D6 genotype and methadone steady-state concentrations

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    4. Lo-Guidice, JM; Allorge, D; Chevalier, D; Debuysere, H; Fazio, F; Lafitte, JJ; Broly, F
      Molecular analysis of the N-acetyltransferase 1 gene (NAT1*) using polymerase chain reaction-restriction fragment-single strand conformation polymorphism assay

      PHARMACOGENETICS
    5. Haffen, E; Vandel, P; Paintaud, G; Broly, F; Vandel, S; Bonin, B; Bizouard, P; Sechter, D; Bechtel, PR
      Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    6. Colombel, JF; Ferrari, N; Debuysere, H; Marteau, P; Gendre, JP; Bonaz, B; Soule, JC; Modgliani, R; Touze, Y; Catala, P; Libersa, C; Broly, F
      Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

      GASTROENTEROLOGY
    7. Marez-Allorge, D; Ellis, SW; Lo Guidice, JM; Tucker, GT; Broly, F
      A rare G(2061) insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype

      PHARMACOGENETICS
    8. de la Moureyre, CSV; Debuysere, H; Fazio, F; Sergent, E; Bernard, C; Sabbagh, N; Marez, D; Lo Guidice, JM; D'halluin, JC; Broly, F
      Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter

      PHARMACOGENETICS
    9. Sabbagh, N; Brice, A; Marez, D; Durr, A; Legrand, M; Lo Guidice, JM; Destee, A; Agid, Y; Broly, F
      CYP2D6 polymorphism and Parkinson's disease susceptibility

      MOVEMENT DISORDERS
    10. Dervieux, T; Medard, Y; Baudouin, V; Maisin, A; Zhang, D; Broly, F; Loirat, C; Jacqz-Aigrain, E
      Thiopurine methyltransferase activity and its relationship to the occurrence of rejection episodes in paediatric renal transplant recipients treated with azathioprine

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    11. Haffen, E; Vandel, P; Broly, F; Vandel, S; Sechter, D; Bizouard, P; Bechtel, PR
      Citalopram: an interaction study with clomipramine in a patient heterozygous for CYP2D6 genotype

      PHARMACOPSYCHIATRY
    12. Vandel, P; Haffen, E; Vandel, S; Bonin, B; Nezelof, S; Sechter, D; Broly, F; Bizouard, P; Dalery, J
      Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    13. DELAMOUREYRE CSV; DEBUYSERE H; SABBAGH N; MAREZ D; VINNER E; CHEVALIER ED; LOGUIDICE JM; BROLY F
      DETECTION OF KNOWN AND NEW MUTATIONS IN THE THIOPURINE S-METHYLTRANSFERASE GENE BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS

      Human mutation
    14. SABBAGH N; MAREZ D; QUEYREL V; LOGUIDICE JM; SPIRE C; VANHILLE P; JORGENSEN C; HACHULLA E; BROLY F
      GENETIC-ANALYSIS OF THE CYTOCHROME-P450 CYP2D6 POLYMORPHISM IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS

      Pharmacogenetics
    15. LEGRANDANDREOLETTI M; STUCKER I; MAREZ D; GALAIS P; COSME J; SABBAGH N; SPIRE C; CENEE S; LAFITTE JJ; BEAUNE P; BROLY F
      CYTOCHROME-P450 CYP2D6 GENE POLYMORPHISM AND LUNG-CANCER SUSCEPTIBILITY IN CAUCASIANS

      Pharmacogenetics
    16. BAUMANN P; BROLY F; KOSEL M; EAP CB
      ULTRARAPID METABOLISM OF CLOMIPRAMINE IN A THERAPY-RESISTANT DEPRESSIVE PATIENT, AS CONFIRMED BY CYP2 D6 GENOTYPING

      Pharmacopsychiatry
    17. DELAMOUREYRE CSV; DEBUYSERE H; MASTAIN B; VINNER E; MAREZ D; LOGUIDICE JM; CHEVALIER D; BRIQUE S; MOTTE K; COLOMBEL JF; TURCK D; NOEL C; FLIPO RM; POL A; LHERMITTE M; LAFITTE JJ; LIBERSA C; BROLY F
      GENOTYPIC AND PHENOTYPIC ANALYSIS OF THE POLYMORPHIC THIOPURINE S-METHYLTRANSFERASE GENE (TPMT) IN A EUROPEAN POPULATION

      British Journal of Pharmacology
    18. MAREZ D; LEGRAND M; SABBAGH N; LOGUIDICE JM; SPIRE C; LAFITTE JJ; MEYER UA; BROLY F
      POLYMORPHISM OF THE CYTOCHROME-P450 CYP2D6 GENE IN A EUROPEAN POPULATION - CHARACTERIZATION OF 48 MUTATIONS AND 53 ALLELES, THEIR FREQUENCIES AND EVOLUTION

      Pharmacogenetics
    19. SABBAGH N; DELAPORTE E; MAREZ D; LOGUIDICE JM; PIETTE F; BROLY F
      NAT2 GENOTYPING AND EFFICACY OF SULFASALAZINE IN PATIENTS WITH CHRONIC DISCOID LUPUS-ERYTHEMATOSUS

      Pharmacogenetics
    20. SABBAGH N; DELAPORTE E; MAREZ D; LOGUIDICE JM; PIETTE F; BROLY F
      NAT2 GENOTYPING AND EFFICACY OF SULFASALAZINE IN PATIENTS WITH CHRONIC DISCOID LUPUS-ERYTHEMATOSUS

      Pharmacogenetics
    21. DELAPORTE E; CATTEAU B; SABBAGH N; GOSSELIN P; BREUILLARD F; DOUTRE MS; BROLY F; PIETTE F; BERGOEND H
      TREATMENT OF DISCOID LUPUS-ERYTHEMATOSUS BY SULFASALAZINE - 11 OBSERVATIONS

      Annales de dermatologie et de venereologie
    22. LOGUIDICE JM; MAREZ D; SABBAGH N; LEGRANDANDREOLETTI M; SPIRE C; ALCAIDE E; LAFITTE JJ; BROLY F
      EVIDENCE FOR CYP2D6 EXPRESSION IN HUMAN LUNG

      Biochemical and biophysical research communications
    23. DALY AK; BROCKMOLLER J; BROLY F; EICHELBAUM M; EVANS WE; GONZALEZ FJ; HUANG JD; IDLE JR; INGELMANSUNDBERG M; ISHIZAKI T; JACQZAIGRAIN E; MEYER UA; NEBERT DW; STEEN VM; WOLF CR; ZANGER UM
      NOMENCLATURE FOR HUMAN CYP2D6 ALLELES

      Pharmacogenetics
    24. BORDET R; BROLY F; DESTEE A; LIBERSA C; LAFITTE JJ
      LACK OF RELATION BETWEEN GENETIC-POLYMORPHISM OF CYTOCHROME P-450IID6AND SPORADIC IDIOPATHIC PARKINSONS-DISEASE

      Clinical neuropharmacology
    25. MAREZ D; LEGRAND M; SABBAGH N; LOGUIDICE JM; BOONE P; BROLY F
      AN ADDITIONAL ALLELIC VARIANT OF THE CYP2D6 GENE CAUSING IMPAIRED METABOLISM OF SPARTEINE

      Human genetics
    26. LEGRAND M; STUCKER I; MAREZ D; SABBAGH N; LOGUIDICE JM; BROLY F
      INFLUENCE OF A MUTATION REDUCING THE CATALYTIC ACTIVITY OF THE CYTOCHROME-P450 CYP2D6 ON LUNG-CANCER SUSCEPTIBILITY

      Carcinogenesis
    27. BROLY F; MAREZ D; SABBAGH N; LEGRAND M; MILLECAMPS S; LOGUIDICE JM; BOONE P; MEYER UA
      AN EFFICIENT STRATEGY FOR DETECTION OF KNOWN AND NEW MUTATIONS OF THECYP2D6 GENE USING SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS

      Pharmacogenetics
    28. MAREZ D; SABBAGH N; LEGRAND M; LOGUIDICE JM; BOONE P; BROLY F
      A NOVEL CYP2D6 ALLELE WITH AN ABOLISHED SPLICE RECOGNITION SITE ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE

      Pharmacogenetics
    29. BROLY F; MAREZ D; LOGUIDICE JM; SABBAGH N; LEGRAND M; BOONE P; MEYER UA
      A NONSENSE MUTATION IN THE CYTOCHROME-P450 CYP2D6 GENE IDENTIFIED IN A CAUCASIAN WITH AN ENZYME DEFICIENCY

      Human genetics
    30. BORDET R; BROLY F; DESTEE A; LIBERSA C
      GENETIC-POLYMORPHISM OF CYTOCHROME-P450 2D6 IN IDIOPATHIC PARKINSON DISEASE AND DIFFUSE LEWY BODY DISEASE

      Clinical neuropharmacology
    31. ROTHMAN N; HAYES RB; BI WF; CAPORASO N; BROLY F; WOOSLEY RL; YIN SN; FENG PW; YOU XJ; MEYER UA
      CORRELATION BETWEEN N-ACETYLTRANSFERASE ACTIVITY AND NAT2 GENOTYPE INCHINESE MALES

      Pharmacogenetics
    32. BROLY F; MEYER UA
      DEBRISOQUINE OXIDATION POLYMORPHISM - PHENOTYPIC CONSEQUENCES OF A 3-BASE-PAIR DELETION IN EXON 5 OF THE CYP2D6 GENE

      Pharmacogenetics
    33. LIBERSA S; CARON J; BROLY F; LACROIX D; LHERMITTE M
      INTERACTION OF PROPAFENONE AND MEXILETINE

      Journal of the American College of Cardiology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/05/20 alle ore 06:06:50